Literature DB >> 29566179

Breast cancer brain metastasis: molecular mechanisms and directions for treatment.

Rute M S M Pedrosa1, Dana A Mustafa1, Riccardo Soffietti2, Johan M Kros1.   

Abstract

The development of brain metastasis (BM) of breast cancer is usually a late event with deleterious effect on the prognosis. Treatment options for intracerebral seeding of breast cancer are limited and, so far, nonspecific. Molecular detailing of subsequent events of penetration, seeding, and outgrowth in brain is highly relevant for developing therapeutic strategies to treat, or prevent, BM.We scrutinize recent literature for molecules and pathways that are operative in the formation of breast cancer BM. We also summarize current data on therapeutic efforts to specifically address BM of breast cancer. Data on molecular pathways underlying the formation of BM of breast cancer are sketchy and to some extent inconsistent. The molecular makeup of BM differs from that of the primary tumors, as well as from metastases at other sites. Current efforts to treat breast cancer BM are limited, and drugs used have proven effects on the primary tumors but lack specificity for the intracerebral tumors.More basic research is necessary to better characterize BM of breast cancer. Apart from the identification of drug targets defined by the intracerebral tumors, also targets in the molecular pathways involved in passing the blood-brain barrier and intracerebral tumor cell growth should be revealed.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29566179      PMCID: PMC6176797          DOI: 10.1093/neuonc/noy044

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  102 in total

1.  Trastuzumab in CSF.

Authors:  B C Pestalozzi; S Brignoli
Journal:  J Clin Oncol       Date:  2000-06       Impact factor: 44.544

2.  NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4.

Authors:  Gregory Helbig; Kent W Christopherson; Poornima Bhat-Nakshatri; Suresh Kumar; Hiromitsu Kishimoto; Kathy D Miller; Hal E Broxmeyer; Harikrishna Nakshatri
Journal:  J Biol Chem       Date:  2003-04-09       Impact factor: 5.157

3.  Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation.

Authors:  Jean-Charles Soria; Ho-Young Lee; Janet I Lee; Luo Wang; Jean-Pierre Issa; Bonnie L Kemp; Diane D Liu; Jonathan M Kurie; Li Mao; Fadlo R Khuri
Journal:  Clin Cancer Res       Date:  2002-05       Impact factor: 12.531

4.  Real-time imaging reveals the single steps of brain metastasis formation.

Authors:  Yvonne Kienast; Louisa von Baumgarten; Martin Fuhrmann; Wolfgang E F Klinkert; Roland Goldbrunner; Jochen Herms; Frank Winkler
Journal:  Nat Med       Date:  2009-12-20       Impact factor: 53.440

5.  Neratinib reverses ATP-binding cassette B1-mediated chemotherapeutic drug resistance in vitro, in vivo, and ex vivo.

Authors:  Xiao-qin Zhao; Jing-dun Xie; Xing-gui Chen; Hong May Sim; Xu Zhang; Yong-ju Liang; Satyakam Singh; Tanaji T Talele; Yueli Sun; Suresh V Ambudkar; Zhe-Sheng Chen; Li-wu Fu
Journal:  Mol Pharmacol       Date:  2012-04-04       Impact factor: 4.436

6.  Heparanase-1 expression is associated with the metastatic potential of breast cancer.

Authors:  Justin B Maxhimer; Roderick M Quiros; Robyn Stewart; Kambiz Dowlatshahi; Paolo Gattuso; Ming Fan; Richard A Prinz; Xiulong Xu
Journal:  Surgery       Date:  2002-08       Impact factor: 3.982

7.  Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.

Authors:  Rachel A Freedman; Rebecca S Gelman; Jeffrey S Wefel; Michelle E Melisko; Kenneth R Hess; Roisin M Connolly; Catherine H Van Poznak; Polly A Niravath; Shannon L Puhalla; Nuhad Ibrahim; Kimberly L Blackwell; Beverly Moy; Christina Herold; Minetta C Liu; Alarice Lowe; Nathalie Y R Agar; Nicole Ryabin; Sarah Farooq; Elizabeth Lawler; Mothaffar F Rimawi; Ian E Krop; Antonio C Wolff; Eric P Winer; Nancy U Lin
Journal:  J Clin Oncol       Date:  2016-02-01       Impact factor: 44.544

8.  Angiotensin II facilitates breast cancer cell migration and metastasis.

Authors:  Sylvie Rodrigues-Ferreira; Mohamed Abdelkarim; Patricia Dillenburg-Pilla; Anny-Claude Luissint; Anne di-Tommaso; Frédérique Deshayes; Carmen Lucia S Pontes; Angie Molina; Nicolas Cagnard; Franck Letourneur; Marina Morel; Rosana I Reis; Dulce E Casarini; Benoit Terris; Pierre-Olivier Couraud; Claudio M Costa-Neto; Mélanie Di Benedetto; Clara Nahmias
Journal:  PLoS One       Date:  2012-04-20       Impact factor: 3.240

9.  CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis.

Authors:  Carol Sheridan; Hiromitsu Kishimoto; Robyn K Fuchs; Sanjana Mehrotra; Poornima Bhat-Nakshatri; Charles H Turner; Robert Goulet; Sunil Badve; Harikrishna Nakshatri
Journal:  Breast Cancer Res       Date:  2006       Impact factor: 6.466

10.  Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience.

Authors:  S Sutherland; S Ashley; D Miles; S Chan; A Wardley; N Davidson; R Bhatti; M Shehata; H Nouras; T Camburn; S R D Johnston
Journal:  Br J Cancer       Date:  2010-02-23       Impact factor: 7.640

View more
  20 in total

1.  Identification of ALDH1A3 as a Viable Therapeutic Target in Breast Cancer Metastasis-Initiating Cells.

Authors:  Daisuke Yamashita; Mutsuko Minata; Ahmed N Ibrahim; Shinobu Yamaguchi; Vito Coviello; Joshua D Bernstock; Shuko Harada; Richard A Cerione; Bakhos A Tannous; Concettina La Motta; Ichiro Nakano
Journal:  Mol Cancer Ther       Date:  2020-03-03       Impact factor: 6.261

2.  Immunological significance of prognostic markers for breast cancer based on alternative splicing.

Authors:  Rong Xu; Qinglong Yang
Journal:  Am J Transl Res       Date:  2022-06-15       Impact factor: 3.940

3.  A brain-enriched lncRNA shields cancer cells from immune-mediated killing for metastatic colonization in the brain.

Authors:  Weiguang Liu; Peng Sun; Lingling Xia; Xilin He; Zhengmiao Xia; Yehong Huang; Wenzhuo Liu; Lulu Li; Liming Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2022-05-26       Impact factor: 12.779

Review 4.  The Key Role of RNA Modification in Breast Cancer.

Authors:  Yang Liu; Tong Zhu; Yi Jiang; Jiawen Bu; Xudong Zhu; Xi Gu
Journal:  Front Cell Dev Biol       Date:  2022-06-01

5.  Radiomic Signatures for Predicting Receptor Status in Breast Cancer Brain Metastases.

Authors:  Xiao Luo; Hui Xie; Yadi Yang; Cheng Zhang; Yijun Zhang; Yue Li; Qiuxia Yang; Deling Wang; Yingwei Luo; Zhijun Mai; Chuanmiao Xie; Shaohan Yin
Journal:  Front Oncol       Date:  2022-06-06       Impact factor: 5.738

6.  GRP94 promotes brain metastasis by engaging pro-survival autophagy.

Authors:  Naiara Santana-Codina; Laia Muixí; Ruben Foj; Rebeca Sanz-Pamplona; Miriam Badia-Villanueva; Agata Abramowicz; Anna Marcé-Grau; Ana María Cosialls; Joan Gil; Ivan Archilla; Leire Pedrosa; Josep Gonzalez; Iban Aldecoa; Angels Sierra
Journal:  Neuro Oncol       Date:  2020-05-15       Impact factor: 12.300

7.  Neoplastic cerebral aneurysm from triple-negative breast cancer: A case report.

Authors:  Eric S Nussbaum; Collin M Torok; Zena M Khalil; John M Pederson
Journal:  Surg Neurol Int       Date:  2021-05-03

Review 8.  The genomic architecture of metastasis in breast cancer: focus on mechanistic aspects, signalling pathways and therapeutic strategies.

Authors:  Yogita Chhichholiya; Prabhat Suman; Sandeep Singh; Anjana Munshi
Journal:  Med Oncol       Date:  2021-07-16       Impact factor: 3.064

9.  [MiR- 4719 inhibits migration and invasion of human breast cancer cells via targeting ARHGAP36].

Authors:  Q Li; Y Qiu; T Jin; M Liu; Y Hou
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2021-06-20

Review 10.  Breast cancer brain metastasis: insight into molecular mechanisms and therapeutic strategies.

Authors:  Yajie Wang; Fangzhou Ye; Yiran Liang; Qifeng Yang
Journal:  Br J Cancer       Date:  2021-07-05       Impact factor: 9.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.